Fecal transplant with immunotherapy and bevacizumab for advanced liver cancer
Part of Cancer clinical trials.
This trial tests combining a fecal transplant (healthy donor bacteria) with two drugs—QL1706 (an immunotherapy) and bevacizumab (a blood vessel blocker)—for people with advanced liver cancer that hasn't been treated before. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced liver cancer (hepatocellular carcinoma) that can't be removed with surgery and hasn't been treated yet.
- You must have a specific stage (BCLC C) and your liver function must be good (Child-Pugh A).
- You must be in generally good health (able to do light activity, ECOG 0-1).
- You cannot have had prior immunotherapy or any systemic therapy for your liver cancer.
- You must not have autoimmune diseases, bleeding risks, or untreated varices in the esophagus or stomach.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This trial tests whether giving a fecal transplant (a procedure that replaces the bacteria in your gut) can help people with advanced liver cancer whose current treatment has stopped working. It may help boost your immune system to fight the cancer.
This trial tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help your liver cancer become sensitive again to treatment that has stopped working. It may help reverse drug resistance and improve outcomes for people with advanced liver cancer.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.